Clinical trial
Fetched
Post
clinicaltrials.gov
ACADIA Pharmaceuticals Inc.
(2022).
Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder.
ClinicalTrials.gov.
ACADIA Pharmaceuticals Inc..
- Publication date
-
9 Aug 2022
- Identifier
-
NCT05523895
- Authors
-
ACADIA Pharmaceuticals Inc.
- Source
- ClinicalTrials.gov
- Reference type
- clinical_trial
- Publisher
- ACADIA Pharmaceuticals Inc.
- Metadata source
- clinicaltrials.gov
Abstract
6-week, randomized, double-blind, fixed-dose, placebo-controlled, parallel group study in children and adolescents (aged 5 to17 years) with autism spectrum disorder (ASD) with irritability, agitation, or self-injurious behaviors to study the efficacy and safety of pimavanserin